Investors & Media

Stock Info
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

BrainStorm Presentation on New Biomarker Data - NurOwn® at the 32nd International Symposium on ALS/MND

Brainstorm’s December 7, 2021 Presentation on new Biomarker data at the 32nd International Symposium on ALS/MND.

Corresponding Presentation

Recent News
May 20, 2024

The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical...

May 14, 2024

Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® Conference call planned for later this quarter to...

Apr 16, 2024

Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK, April 16, 2024 /PRNewswire/ -- BrainStorm Cell...

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds